HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Immunotherapy, tumor profiling fill ‘gigantic knowledge gap’ in bladder cancer
-
- Adjunctive systemic therapy: A reasonable option for patients with muscle-invasive bladder cancer Donald L. Trump, MD, FACP
- How the making of it matters Christine Cserti-Gazdewich, MD, FRCPC
- AACR president: ‘Full spectrum’ of cancer research must remain priority
- American Society for Radiation Oncology names honorary member
- ASH presents research training awards to seven fellows
- City of Hope physician–researcher receives Ho-Am Prize in Medicine
- Experts: Promotion of HPV vaccination must focus on cancer prevention
- FDA’s cancer drug director to lead Oncology Center of Excellence
-
- Fox Chase announces staff appointments
- Memorial Sloan Kettering Cancer Center names pediatrics chairman
- Rutgers Cancer Institute appoints co-program leader
- Task force: Evidence insufficient to determine benefits, harms of routine screening pelvic exams
- University of Maryland professor receives award for hyperthermic oncology research
- Word salad: What’s for dessert? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Axillary pathologic complete response linked to longer survival in breast cancer
- Caplacizumab induces rapid response for acquired TTP
-
- Coffee no longer classified as a carcinogen
- Earlier hospice, avoidance of ICU improve family members’ perceptions of end-of-life care
- Many prevention, screening guidelines do not adequately explain benefits, risks
- Obesity may increase risk for pediatric VTE
- Palliative care reduces financial burden of patients with advanced cancer, comorbidities
- PANVAC plus docetaxel may have clinical benefit for metastatic breast cancer
- Product age, preparation method may influence mortality risk following blood transfusion
- Rates of reoperation after breast-conserving surgery remain high
-
- Addition of capecitabine to adjuvant chemotherapy extends survival in pancreatic cancer
- Biomarkers predict response to pembrolizumab in recurrent, metastatic HNSCC
- CPX-351 improves survival for older patients with high-risk secondary AML
- Daratumumab combination improves PFS, ORR in relapsed, refractory multiple myeloma
- Extended hormone therapy prolongs DFS, maintains quality of life
- Extended lymph node dissection may improve survival for patients with bladder cancer
- First-line atezolizumab demonstrates meaningful activity in patients with metastatic urothelial cancer
- Global variation in cancer drug prices does not reflect affordability
-
- Inotuzumab ozogamicin improves outcomes in adult ALL
- Intraperitoneal chemotherapy after ovarian cancer surgery slows disease progression
- Liquid biopsy assay exhibits efficacy similar to traditional tumor biopsy
- Local consolidative therapy prolongs PFS in patients with metastatic NSCLC
- Many patients with terminal cancer receive aggressive end-of-life treatment
- Nilotinib induces treatment-free remission in patients with chronic phase CML
- Novel therapy shows promise for advanced gastric cancer
- Palbociclib improves PFS in patients with HER-2–negative advanced breast cancer
-
- PCP training improves skin cancer screening rates, diagnostic outcomes
- Pembrolizumab plus ipilimumab safe, effective for advanced melanoma
- Plasma, urine genotyping effectively identify mutations in NSCLC
- Preoperative chemoradiotherapy extends survival in esophagogastric junction adenocarcinoma
- Proton therapy may prolong OS in stage II, III NSCLC
- Survey identifies perceived barriers to data sharing
- Meeting Update: ASCO highlights therapeutic advances in multiple cancer subtypes